The meta analysis showed that therapy with metformin use was associated with decreased. Epidemiological, preclinical and clinical evidence supports the use of metformin as a cancer therapeutic. Metformin for cancer prevention and therapy for colon, pancreatic, breast, liver and bladder cancer6. We conducted a comprehensive literature search for all pertinent studies addressing metformin use and. Metformin, an insulinlowering agent, has been associated with decreased cancer risk in epidemiologic studies in diabetic patients. Diabetics on metformin have less cardiovascular disease than other diabetics.
Metformin for liver cancer prevention in patients with type 2 diabetes. However, the evidence of the effects of metformin on ovarian cancer is still limited and inconclusive. For each metaanalysis on the association between metformin use and cancer risk or survival outcomes, the summary effect was synthesized. The os meta analysis was performed following the appropriate cochrane guidelines 22. Metaanalysis of studies using metformin as a reducer for. Jul 19, 2017 we conducted a meta analysis to analyse the effect of metformin on survival of pancreatic cancer patients at various stages. The meta analysis was performed on 6 studies of a total of 1,579 metformin users with lung cancer. The effect of metformin on survival of patients with. The association between metformin and the lung cancer risk of patients with type 2 diabetes mellitus t2dm remains controversial. Frontiers the potential effect of metformin on cancer. As a result, it has become the most widely prescribed antidiabetes drug worldwide. Summary effect estimates were derived using a randomeffects meta analysis model. Cancer risk in diabetic patients treated with metformin. The meta analysis aims to investigate whether metformin improves the survival of diabetic crc patients.
Pdf metformin and cancer risk in diabetic patients. Metformin may be able to extend health and lifespans in the general population. Apr 26, 2016 metformin or also called glucophage, is an oral prescription medication used to treat type 2 diabetes. The inclusion criteria in the metaanalysis are as follows. Metformin x breastcancer x diabetesmellitus x survival x meta analysis abstract background. Jan 01, 2019 therefore, this drug can be used as a complementary therapeutic agent for cancer treatment and prevention. Monotherapy with metformin versus sulfonylureas and risk of.
The os metaanalysis was performed following the appropriate cochrane guidelines 22. Research paper the clinical effect of metformin on the. Therefore, the present meta analysis on epidemiological studies was performed to explore this issue. The beneficial effects of metformin on cancer prevention and.
Reduced risk of colorectal cancer with metformin therapy in. Therefore, the present metaanalysis on epidemiological studies was performed to explore this issue. Metformin use is associated with better survival of breast. International journal of molecular sciences article metaanalysis of microarray expression studies on metformin in cancer cell lines hansjuergen schulten 1, and sherin bakhashab 2,3 1 center of excellence in genomic medicine research, department of medical laboratory technology, faculty of applied medical sciences, king abdulaziz university, p.
Dec 23, 2011 metformin does not appear to activate ampk directly, but inhibits mitochondrial complex i of the respiratory chain, leading to an increase in the amp. Metformin improves overall survival of colorectal cancer patients with. As such, a significant association 31% reduction between metformin use and cancer incidence pancreatic and hcc was reported in a meta analysis of 11 studies consisting of 4042 patients with cancer and diabetes. Metformin anticancer treatment or cancer prevention. Diabetics on metformin have less cancer than nondiabetics and other diabetics. Introduction metformin 1,1dimethylbiguanide is the most widely. Meta analysis suggests benefits of metformin therapy in patients with comorbid kidney or heart disease. Overall cancer incidence was reduced by 31% summary relative risk srr. We performed a comprehensive literature search and metaanalysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients, using pubmed, isi web of science, embase, and the cochrane library until may 2009. This metaanalysis was performed to provide the evidence of clinical efficacy and safety of metformin in t1dm. Metformin is a safe, effective and welltolerated agent, which is recommended as the first line oral hypoglycemic in treatment of newly diagnosed type ii diabetes.
This drug is inexpensive, has an excellent safety profile, and can be safely combined with other antidiabetes agents 2. Association of metformin use with cancer incidence and. Background and aim although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma. Metformin use is associated with reduced incidence and. Pubmed, embase, and the cochrane library databases were searched for observational studies. Oct 27, 2017 a meta analysis of studies comparing outcomes between metformin users and non metformin users for cancers treated curatively at an early stage found that, in colorectal cancer above left, metformin use was associated with longer recurrence free survival, overall survival and cancer specific survival. Metformin and colorectal cancer risk in diabetic patients metformin and colorectal cancer risk in diabetic patients. Metaanalysis of studies using metformin as a reducer for liver. The summary risk estimates for the associations of metformin treatment with. In the mean time longterm rcts are called for to confirm the clinical benefit of metformin. However, the evidence for a cancer preventive effect for metformin has not been consistently demonstrated. Our meta analysis indicated that metformin was negatively associated with the incidence of overall cancer, liver cancer, pancreatic cancer, colorectal cancer and breast cancer as well as the mortality of overall cancer, liver cancer and breast cancer. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Dunn4, leslie ford5, andrea decensi6, and eva szabo7 abstract.
As such, a significant association 31% reduction between metformin use and cancer incidence pancreatic and hcc was reported in a metaanalysis of 11 studies consisting of 4042 patients with cancer and diabetes. Association between metformin and cancer incidencemortality across selected studies was computed as a summary relative risk srr with. Furthermore, a meta analysis showed a significantly lower risk of colorectal cancer with metformin therapy among patients with type 2 diabetes, suggesting a potential role of metformin in chemoprevention for cancer potentially across indications. Metformin, a biguanide derived from the french lilac, has become the preferred firstline therapy for the treatment of type 2 diabetes 1. Metformin therapy has been associated with a reduced risk of endometrial cancer, liver cancer, lung cancer, pancreatic cancer, and colorectal cancer, but not related with breast cancer. Previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer ec, while the results have been inconsistent. A metaanalysis demonstrated that metformin appeared to have a direct antihepatocellular carcinoma hcc effect in animal models. Observational studies have suggested that metformin decreases the incidence of several common cancers.
Our objective was to enhance the precision of estimates of the effect of metformin on the risk of anysite and sitespecific cancers in patients with diabetes. Effect of metformin on mortality among diabetic cancer patients. Metformin, an antidiabetic drug, has emerged as a new adjunctive strategy for different cancer types, including endometrial cancer. Original article the effects of metformin on ovarian. Sep 18, 2019 the search strategy used the following terms. Association of the metformin with the risk of lung cancer. However, limitations include heterogeneous comparator types, absent cancer data from two trials, and short followup, especially for mortality. Monotherapy with metformin versus sulfonylureas and risk of cancer in. Introduction diabetes mellitus is the most common metabolic. Recently, metformin, the most widely prescribed biguanide, has emerged as a potential anticancer agent. Survival benefits of metformin for colorectal cancer patients with diabetes. We conducted a comprehensive literature search for all pertinent studies addressing metformin use.
Reduced risk of colorectal cancer with metformin therapy. Jul 31, 2012 observational studies have suggested that metformin decreases the incidence of several common cancers. Our metaanalysis indicated that there was no association of metformin use with prostate cancer risk, which further enriched the knowledge of relationship between metformin therapy and cancer development. Metformin use is associated with reduced incidence and improved survival of endometrial cancer.
The metaanalysis was conducted in accordance with the guidelines for the metaanalysis of observational studies in epidemiology moose and the prisma statement 18, 19. Metformin x breastcancer x diabetesmellitus x survival x metaanalysis abstract background. We performed a comprehensive literature search and metaanalysis. Previous metaanalyses have shown that the antidiabetic agent metformin is.
Metformin improves overall survival of colorectal cancer. Reduced risk of lung cancer with metformin therapy in. By interrogating the gene expression omnibus geo for microarray expression data, we identified eight eligible submissions, representing five different studies, that employed various conditions. Repositioning metformin for cancer prevention and treatment.
Metformin reduces allcause mortality and diseases of. The beneficial effects of metformin on cancer prevention. A metaanalysis yunliangtang,1 lingyanzhu,1 yuli,2 jiaoyu,1 jiaowang,1 xiangxiazeng,1. Understanding the benefit of metformin use in cancer. Indeed, a number of preclinical studies support this pleiotropic effect of metformin on cancer.
Breast cancer is a leading cause of cancer mortality in developed countries. Background a growing body of evidence has suggested that metformin potentially reduces the risk of cancer. A summary of the main characteristics for studies of breast, colorectal and prostate cancer is presented in table 1table 1, and a table of study characteristics for. Endometrial cancer is one of the most common gynecological cancers, which is frequently preceded by atypical endometrial hyperplasia, a premalignant lesion. Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than do diabetic patients not receiving metformin, but findings on salvage treatment have been inconsistent. Metformin users also had reduced cancer compared to nondiabetics rate ratio 0. Metaanalysis showed that the risk of developing lung cancer was lower in metformin users than in those without metformin or0. Results of the meta analysis showed that the incident cancer risks were significantly decreased for cancers of the lung in metformin users, compared with non metformin users or0. The summary risk estimates for the association between metformin. Metformin in cancer treatment and prevention annual. The summary rr for exposure to metformin versus su was the measure of interest. Research article cancer prevention research metformin and. The search was carried out on observational studies and trials, without language restrictions.
We conducted a search on medline, embase, and the cochrane library for relevant studies published before may 2014 based on metformin and diabetes mellitus, type 1. Pubmed, embase, and cochrane library were searched till july 1, 2016. Apr 18, 2018 previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer ec, while the results have been inconsistent. Diabetic population has a higher risk of colorectal cancer crc incidence and mortality than nondiabetics. The role of metformin in crc prognosis is still controversial. Building the clinical evidence on metformin and cancer. The aim of the study was to evaluate the association between metformin use and cancer incidence and mortality in diabetic patients.
Thus, the potential use of metformin as a novel cancer prevention strategy has generated much. Therefore, this drug can be used as a complementary therapeutic agent for cancer treatment and prevention. We performed a comprehensive literature search and meta analysis. A metaanalysis revealed that cancer patients with preexisting diabetes have an increased risk of mortality compared with those without diabetes. Metformin improves overall survival of colorectal cancer patients with diabetes. We conducted a metaanalysis to analyse the effect of metformin on survival of pancreatic cancer patients at various stages. Pubmed, embase, and the cochrane library databases were searched for observational. Metformin has been associated with cancer risk reduction in recent epidemiologic studies in diabetic patients 3446. We performed a comprehensive literature search and meta analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients, using pubmed, isi web of science, embase, and the cochrane library until may 2009. Although a metaanalysis demonstrated that metformin was significantly associated with a lower incidence of ovarian cancer in patients with diabetes 30, studies on the use of metformin to prevent ovarian cancer in.
Improved understanding of these issues will increase the chances for successful application of metformin as an inexpensive, welltolerated, and effective anticancer agent. In summary, this large metaanalysis of cohort studies did not find an association between metformin use and risk of prostate cancer. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. We performed a systematic search of pubmed, embase, cochrane, and web. Metformin efficacy and safety for colorectal polyps. Research article metformin and cancer risk in diabetic patients. Metformin and lung cancer risk of patients with type 2. Research design and methods the pubmed and sciverse scopus databases were searched to identify studies that examined the effect of metformin therapy on colorectal cancer among patients with type 2 diabetes. Eligible trials also showed no significant effect of metformin on allcause mortality.
Original article the effects of metformin on ovarian cancer. The effect of metformin therapy on incidence and prognosis. Biguanides have been developed for the treatment of hyperglycemia and type 2 diabetes. It decreases the production of excess sugar by the liver and helps maintain normal blood sugar levels. Metformin reduces allcause mortality and diseases of ageing.
Metformin appears to extend health and life spans independent of its effect on diabetes. We conducted searches of pubmed, embase and the cochrane central register of controlled trials to identify studies evaluating risk or survival data of ovarian cancer in diabetic patients taking metformin versus those not. The pleiotropic anticancer effects of mtf on cancer cells have not been fully explored yet. A metaanalysis revealed that cancer patients with preexisting diabetes have an increased risk of mortality compared with. Meireles and others published effects of metformin on endometrial cancer. Several studies have demonstrated that metformin mtf acts with variable efficiency as an anticancer agent. The effect of metformin therapy on incidence and prognosis in prostate cancer. Methodsprincipal findings we performed a search of medline, embase, isi web of science, cochrane library, and clinicaltrials. Objective the potential therapeutic effects of metformin on several cancers were reported. Research article metformin and cancer risk and mortality.
Metformin for liver cancer prevention in patients with type 2. Metformin is a wellestablished, effective agent for the management of type 2 diabetes mellitus. The effect of metformin therapy on incidence and prognosis in. We performed a metaanalysis of randomized clinical trials to investigate the effect of metformin on biomarkers associated with breast cancer outcomes and to explore the doseresponse relationship. The effect of metformin on biomarkers associated with breast. Efficacy and safety of metformin for patients with type 1. The ability of metformin to lower circulating insulin may be particularly important for the. Metformin, cancer, molecular action, clinical evidence. Preclinical evidence suggests that metformin appears to inhibit the. Association of metformin and risk of liver cancer are mainly studied in animal and observational human studies. However, findings regarding breast cancer have been mixed.
651 117 1533 12 539 559 1662 468 1397 1053 464 1563 1114 1118 669 1652 1588 944 1309 1326 1101 261 545 1436 1378 335 953 71 51 111 1445 1223 114 1435 1050 176 201